Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.56 |
| ▸ | MDM4 | O15151 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157081 | 1.00 | TLR2 (0.58) | TLR2MDM2MDM4TP53KMT2A | |
| SCHEMBL29466503 | 1.00 | TLR2 (0.58) | TLR2MDM2MDM4TP53KMT2A | |
| SCHEMBL2089279 | 1.00 | TLR2 (0.58) | TLR2MDM2MDM4TP53KMT2A | |
| SCHEMBL29602166 | 1.00 | TLR2 (0.58) | TLR2MDM2MDM4TP53KMT2A | |
| SCHEMBL29514436 | 1.00 | TLR2 (0.58) | TLR2MDM2MDM4TP53KMT2A | |
| SCHEMBL29865029 | 1.00 | TLR2 (0.58) | TLR2MDM2MDM4TP53KMT2A | |
| SCHEMBL3624369 | 1.00 | TLR2 (0.58) | TLR2MDM2MDM4TP53KMT2A | |
| Hydrochloric Acid SCHEMBL25356870 | 0.99 | TLR2 (0.59) | TLR2MDM2MDM4TP53KMT2A | |
| Hydrochloric Acid SCHEMBL20604023 | 0.99 | TLR2 (0.59) | TLR2MDM2MDM4TP53KMT2A | |
| Hydrochloric Acid SCHEMBL29736996 | 0.99 | TLR2 (0.59) | TLR2MDM2MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026984-B | Rhodamine B modified lysine derivative and synthetic method and application thereof | HEFEI UNIVERSITY OF TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122036916-A | Ruitalu Process for producing peptide | 哈尔滨吉象隆生物技术有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-118878622-B | Green chemical synthesis method of illegal stand | 中肽生化有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | SHILPA PHARMA LIFESCIENCES LIMITED (IN) | 2025-07-24 | — | — | US | claimed |
| WO-2025130972-A1 | SYNTHETIC METHOD FOR TIRZEPATIDE | 深圳翰宇药业股份有限公司 | 2025-06-26 | — | — | WO | claimed |
| CN-119954690-A | Protection of amino acid side chains by host-guest affinity molecules in peptide synthesis | 马涌 | 2025-05-09 | — | — | CN | claimed |
| WO-2025092769-A1 | PREPARATION METHOD FOR DUAL GIP AND GLP-1 RECEPTOR AGONIST | 博瑞生物医药（苏州）股份有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119930756-A | Preparation method of dual receptor agonist of GIP and GLP-1 | 博瑞生物医药（苏州）股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119350471-B | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119874813-A | Short peptide compound and preparation method thereof, cosmetic composition and application | 常州市智态生创科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-114262370-A | Anemone violaceum polypeptide toxin Hc-GQ and preparation method and application thereof | 海南医学院 | 2022-04-01 | — | — | CN | claimed |
| CN-113135988-B | Preparation method of thymosin beta 4 | 润辉生物技术（威海）有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-114249797-A | Small molecule polypeptide medicament based on GSDMD protein RFWK motif and preparation method and application thereof | 南京医科大学 | 2022-03-29 | — | — | CN | claimed |
| CN-114249810-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-113880936-B | Solid-phase synthesis method of abamectin | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-113861273-B | Synthesis method of myristoyl pentapeptide-4 | 浙江湃肽生物有限公司深圳分公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114230633-A | Polypeptide with oxidative stress damage repairing function and preparation method and application thereof | 浙江湃肽生物有限公司深圳分公司 | 2022-03-25 | — | — | CN | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-11261448-B2 | SNAP25 antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-03-01 | — | — | US | claimed |
| CN-109180803-B | Somatostatin and preparation method and pharmaceutical composition thereof | 成都天台山制药有限公司 | 2022-02-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | GLP1R, IAPP, VIP | TLR2 4425/4885MDM2 1541/4885MDM4 1231/4885 |
| US-11261448-B2 | SNAP25 antisense oligonucleotides | RBM25, SNAP23, UPF1 | TLR2 3177/4885MDM2 4318/4885MDM4 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.